# Inhibrx CEO Says OX40 Agonist Shows Durable Progression-Free Survival in Head and Neck Cancer Trial

Inhibrx Biosciences’ chief executive officer has stated that progression-free survival data from a phase 2 study of the company’s OX40 agonist leave “no question” about the therapy’s durability in treating head and neck cancer. The CEO argued that the 9.6 months of progression-free survival observed in the trial demonstrate the treatment’s sustained effect.

The statement follows the release of results from the mid-stage study, which evaluated the OX40 agonist in patients with head and neck cancer. The CEO characterized the dataset as “profound” and said it supports hopes for accelerated approval of the therapy. No additional details on trial design, patient numbers, or safety outcomes were provided in the announcement.

**Why this matters for biotech and medicine**

OX40 agonists are a class of immunotherapies designed to enhance the activity of T cells by targeting the OX40 receptor, a costimulatory molecule on activated immune cells. By amplifying the immune response against tumors, these agents aim to improve outcomes in cancers that have been resistant to other treatments. Head and neck squamous cell carcinoma remains a difficult-to-treat malignancy, and durable responses are uncommon with existing therapies. If confirmed in larger trials, the 9.6-month progression-free survival result could represent a meaningful advance for patients who have limited options. The data also add to the growing evidence that OX40 agonists may have a role in combination or monotherapy regimens across multiple solid tumors.

Source: [original report](https://www.fiercebiotech.com/biotech/inhibrxs-profound-dataset-boosts-hopes-accelerated-approval-ox40-agonist)